the Ministry of Health and Family Welfare. The formation of the dedicated Ministry of AYUSH marked a significant step in streamlining policy, regulation, and research efforts specific to traditional Indian medicine.

Regulatory Control and Oversight

• The Ministry of AYUSH governs regulatory standards for AYUSH drugs, formulations, and clinical studies.
• The Central Council of Indian Medicine (CCIM) and Central Council of Homeopathy (CCH) are responsible for educational and clinical guidelines.
• Drugs manufactured under the AYUSH banner must follow provisions under the Drugs and Cosmetics Act, specifically Chapters IVA and IVB.
• Good Clinical Practices (GCP) Guidelines for ASU&H drugs were introduced in 2013 and revised subsequently.

Coordination with CDSCO

While AYUSH clinical trials are under the Ministry of AYUSH, CDSCO and DCGI play a role when trials involve pharmacovigilance data submission, safety monitoring, or approval of AYUSH formulations containing new chemical entities (NCEs).

Core Clinical Trial Insights

1. Clinical Trial Design for AYUSH Studies

AYUSH trials often require adaptation from conventional ICH-GCP standards due to the holistic and individualized approach inherent to traditional systems. Common study designs include:

• Open-label, non-randomized pilot studies
• Observational cohort studies in Ayurveda hospitals
• Randomized controlled trials (RCTs) with herbal comparators
• Pragmatic trials comparing AYUSH therapies to standard of care

2. GCP Guidelines for ASU&H Drugs

The Ministry of AYUSH introduced a separate set of GCP Guidelines in 2013 tailored to AYUSH systems. These cover:

• Preclinical and toxicity data requirements for ASU formulations
• Patient eligibility and informed consent specific to AYUSH practices
• Roles and responsibilities of AYUSH investigators and Ethics Committees
• Documentation and data archiving adapted for multi-component herbal interventions

Researchers are encouraged to comply with both AYUSH-GCP and ICMR Ethical Guidelines to maintain trial validity and scientific integrity.

3. Ethics and AYUSH Trials

Ethical considerations in AYUSH clinical research include:

• Non-exploitation of tribal or indigenous populations with traditional knowledge
• Disclosure of polyherbal formula compositions in informed consent
• Evaluation of long-term safety for chronic use therapies like Rasayanas

All AYUSH trials involving human subjects must be approved by Ethics Committees registered with CDSCO and, where applicable, by the respective AYUSH Research Councils.

4. Role of Research Councils

The Central Councils play a key role in protocol development, grant disbursement, site monitoring, and publication. Examples include:

• CCRAS: Ayurveda trials on rheumatoid arthritis, diabetes, and COVID-19 management.
• CCRH: Homeopathy RCTs for dengue, influenza-like illness.
• CCRYN: Yoga research in cardiovascular health and cancer therapy adjuncts.

5. Registration and CTRI Listing

As per ICMR guidelines and CDSCO directives, AYUSH trials must be registered with the Clinical Trials Registry – India (CTRI). The registration must include clear details of:

• Trial design and methodology
• Intervention components and dosage
• Primary and secondary endpoints
• Sponsor and funding source

6. Integration into Mainstream Clinical Research

Efforts are underway to:

• Standardize AYUSH terminologies and diagnostic criteria
• Digitize patient records and trial databases through NAMASTE portal
• Enable joint trials between allopathy and AYUSH under integrative medicine programs

7. Intellectual Property and Traditional Knowledge

AYUSH clinical research must navigate carefully around the Traditional Knowledge Digital Library (TKDL), which documents more than 2.9 lakh formulations in Ayurveda, Siddha, and Unani. Researchers cannot patent formulations already present in TKDL unless they demonstrate significant innovation or new clinical application.

Best Practices & Preventive Measures

• Use standardized extracts and documented monographs to ensure batch consistency
• Include botanist-certified raw material authentication
• Conduct stability and shelf-life studies prior to trial initiation
• Ensure trial insurance includes AYUSH treatments, which some policies exclude
• Involve community leaders when recruiting patients in rural or traditional health contexts

Scientific & Regulatory Evidence

• Ministry of AYUSH GCP Guidelines for ASU&H Drugs (2013)
• ICMR National Ethical Guidelines (2017)
• CDSCO guidance on herbal and traditional medicine trials
• WHO Traditional Medicine Strategy 2014–2023
• Drugs and Cosmetics Act, Chapter IVA

Special Considerations

1. Pediatric and Geriatric AYUSH Trials

Special populations require dose adjustments and additional safety monitoring. Many Ayurveda products are Rasayanas or immunomodulators used in children, requiring tailored study designs.

2. Digital Trials and AYUSH

Initiatives like the AYUSH Clinical Case Repository (ACCR) and digital e-Aushadhi portals are aiding remote data collection and post-marketing surveillance of AYUSH products.

3. Language and Cultural Barriers

AYUSH trials must navigate multilingual patient populations. Informed consent and trial documentation should be available in vernacular languages with layperson terminology for herbs, procedures, and diagnoses.

When Sponsors Should Seek Regulatory Advice

• When conducting trials involving novel dosage forms or delivery methods (e.g., transdermal Ayurveda)
• When the study involves integrative therapy with allopathic comparators
• When IP is sourced from tribal formulations or traditional healers
• When trial scale requires DCGI or CDSCO registration for safety monitoring
• If trials are meant for global registration or publication in indexed journals

FAQs

1. Are AYUSH trials subject to CDSCO regulation?

AYUSH trials are regulated by the Ministry of AYUSH, but CDSCO involvement is needed for pharmacovigilance, SAEs, and trials involving new chemical or biological entities.

2. Do AYUSH trials need to follow ICH-GCP?

Not mandatorily. They must follow AYUSH-specific GCP guidelines, though alignment with ICH-GCP is encouraged for global credibility.

3. Can AYUSH trials be placebo-controlled?

Yes, though ethical concerns exist in certain chronic disease trials. Pragmatic comparators are often preferred.

4. What is NAMASTE portal?

“National AYUSH Morbidity and Standardized Terminologies Electronic Portal” — it standardizes diagnostic and morbidity terminology across Indian systems of medicine.

5. Are AYUSH trials eligible for government funding?

Yes. Funding is available through research councils like CCRAS, CCRH, and extramural grants from the Ministry of AYUSH.

6. Can AYUSH practitioners be Principal Investigators?

Yes, provided they are registered with the respective councils (CCIM or CCH) and have trial-related training and institutional affiliation.

Conclusion

AYUSH clinical research in India is entering a new phase of scientific rigor, regulatory accountability, and global relevance. With dedicated frameworks, specialized GCP guidelines, and institutional support, sponsors and investigators have ample opportunity to explore evidence-based traditional medicine within India’s growing clinical trial ecosystem.